NASDAQ:PDLI - PDL BioPharma Stock Price, Forecast & News

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL BioPharma announced that its Board of Directors has initiated a stock buyback plan on Monday, September 24th 2018, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 27.3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

PDL BioPharma Inc (NASDAQ:PDLI) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported $0.08 EPS for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.04. The biotechnology company earned $44.17 million during the quarter. View PDL BioPharma's Earnings History.

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for PDL BioPharma.

1 brokers have issued 12-month price targets for PDL BioPharma's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's share price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 8.0%. View Analyst Price Targets for PDL BioPharma.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

News stories about PDLI stock have trended somewhat positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PDL BioPharma earned a news impact score of 0.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for PDL BioPharma.

PDL BioPharma saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 10,150,000 shares, a drop of 27.3% from the December 15th total of 13,960,000 shares. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 7.4 days. Currently, 9.1% of the company's shares are short sold. View PDL BioPharma's Current Options Chain.

Some companies that are related to PDL BioPharma include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Advanced Micro Devices (AMD), Opko Health (OPK), Canopy Growth (CGC), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Cara Therapeutics (CARA) and Prospect Capital (PSEC).

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PDLI stock can currently be purchased for approximately $3.26.

PDL BioPharma has a market capitalization of $372.24 million and generates $198.11 million in revenue each year. The biotechnology company earns $-68,860,000.00 in net income (profit) each year or $0.37 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.View Additional Information About PDL BioPharma.

The official website for PDL BioPharma is http://www.pdl.com/.

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]